Annotation Detail

Information
Associated Genes
FGFR2
Associated Variants
FGFR2 AMPLIFICATION ( ENST00000457416.7 )
FGFR2 AMPLIFICATION ( ENST00000457416.7 )
Associated Disease
breast cancer
Source Database
CIViC Evidence
Description
Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11 nonamplified cell lines. Dovitinib inhibited tumor growth and caused regression in both a FGFR1- and FGFR2-amplified xenograft model. 81 patients were enrolled in the trial and treated with dovitinib. 2 patients were reported to harbor FGFR2 amplifications and both had a reduction in tumor size of 18.5 and 28.2%, respectively. When FGFR1, FGF3 and FGFR2 amplifications were combined, a combined FGF-pathway amplified patient group had a higher mean reduction in target lesion size than patients with FGF-non-amplified tumors.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1605
Gene URL
https://civic.genome.wustl.edu/links/genes/22
Variant URL
https://civic.genome.wustl.edu/links/variants/629
Rating
2
Evidence Type
Predictive
Disease
Breast Cancer
Evidence Direction
Supports
Drug
Dovitinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
23658459
Drugs
Drug NameSensitivitySupported
DovitinibSensitivitytrue